U.S. patent number 3,897,363 [Application Number 05/387,419] was granted by the patent office on 1975-07-29 for blood control standard.
This patent grant is currently assigned to Baxter Laboratories, Inc.. Invention is credited to Anthony J. Fontana, Allan L. Louderback.
United States Patent |
3,897,363 |
Louderback , et al. |
July 29, 1975 |
Blood control standard
Abstract
A blood control standard is prepared from anticoagulant stored
blood plasma containing elevated levels of dextrose by aerobic
fermentation with yeast in the late log phase or in the stationery
phase of the yeast growth to selectively destroy dextrose without
adversely affecting the protein constituents of said blood
plasma.
Inventors: |
Louderback; Allan L. (Temple
City, CA), Fontana; Anthony J. (Glendora, CA) |
Assignee: |
Baxter Laboratories, Inc.
(Morton Grove, IL)
|
Family
ID: |
23529784 |
Appl.
No.: |
05/387,419 |
Filed: |
August 10, 1973 |
Current U.S.
Class: |
436/16; 435/13;
435/802; 436/14; 436/18; 424/530; 435/269; 435/942; 436/17 |
Current CPC
Class: |
G01N
33/96 (20130101); A61K 35/16 (20130101); C12Q
1/56 (20130101); Y10T 436/107497 (20150115); Y10T
436/108331 (20150115); Y10T 436/106664 (20150115); Y10S
435/942 (20130101); Y10T 436/104998 (20150115); Y10S
435/802 (20130101) |
Current International
Class: |
A61K
35/16 (20060101); C12Q 1/56 (20060101); G01N
33/96 (20060101); C09k 003/00 (); G01n 031/00 ();
G01n 033/00 () |
Field of
Search: |
;252/408 ;23/23B
;424/101 ;195/11,37 |
References Cited
[Referenced By]
U.S. Patent Documents
Foreign Patent Documents
|
|
|
|
|
|
|
1,287,083 |
|
Jan 1969 |
|
DT |
|
45-13576 |
|
May 1970 |
|
JA |
|
Other References
"The Chemistry and Biology of Yeasts," edited by A. H. Cook,
Academic Press Inc., N.Y., 1958, pp. 252-275..
|
Primary Examiner: Padgett; Benjamin R.
Assistant Examiner: Gron; Teddy S.
Attorney, Agent or Firm: Meyer; Scott J. Altman; Louis
Claims
What is claimed is:
1. The method of making a blood control standard from anticoagulant
stored, defibrinated blood plasma containing elevated levels of
dextrose which comprises selectively destroying dextrose in said
blood plasma by aerobic fermentation with agitation utilizing 0.1
to 10 grams of a yeast in the negative acceleration phase or in the
stationary phase of the yeast growth per liter of said plasma and
separating particulate residue from the fermentation product.
2. The method of claim 1 in which the yeast is Saccharomyces
cerevisiae.
3. The method of claim 1 in which the blood plasma is incubated
with the yeast for about 12 to about 24 hours at about 20.degree.
to about 25.degree. C.
4. The method of claim 1 in which the dextrose in said blood plasma
is reduced from an initial level of about 300 to 500 mg. per 100
ml. to a final level of about 0 to 50 mg. per 100 ml.
5. The method of claim 1 in which the yeast is Saccharomyces
cerevisiae, the blood plasma is incubated with said yeast for about
12 to about 24 hours at about 20.degree. to about 25.degree. C, and
in which the dextrose in said blood plasma is reduced from an
initial level of about 300 to 500 mg. per 100 ml. to a final level
of about 0 to 50 mg. per 100 ml.
6. A liquid blood control standard comprising anticoagulant-stored
blood plasma containing from about 300 to 500 mg. per 100 ml. of
dextrose which is defibrinated, reacted with yeast by aerobic
fermentation with agitation utilizing from 0.1 to 10 grams of said
yeast per liter of said plasma in the negative acceleration phase
or in the stationary phase of the yeast growth to selectively
destroy said dextrose and reduce its concentration to a level of
about 0 to 50 mg. per 100 ml, and separated from particulate
residue.
Description
This invention relates to a blood control standard and method of
preparation thereof.
Blood serum is a complex biological fluid containing numerous
components of substantial physiological importance. In the normal
or average healthy person the concentrations of these components
fall within certain reasonably well-defined limits. When one or
more of these components is determined upon analysis to fall
outside of these acceptable limits, various diseases or
pathological conditions of the body systems are indicated.
In recent years various automated procedures have been developed
for conveniently analyzing multiple components of blood serum.
Illustrative of the analytical equipment for these purposes are the
Technicon "Auto-Analyzer," the Warner Chillcott "Robot Chemist,"
the Beckman "Discrete Analyzer" and the Hycel "Mark X." These
instruments are capable of rapidly and sequentially determining the
concentrations of a host of blood serum components in a single
sample, for example, up to a dozen or more values.
In the performance of the analytical tests made by the above and
similar equipment on blood serum and other biological samples, it
is necessary to use laboratory standard materials or so-called
"reference or control standards" for purposes of calibration and
control of the instrument. Accurate results in the use of these
instruments, particularly in the case of multi-automated
procedures, are dependent upon rigid and constant standardization
of the biochemical determinations.
Illustrative of the control standards used in actual practice are
the freeze-dried serum which is reconstituted with aqueous ammonium
bicarbonate prior to use as described in U.S. Pat. No. 3,466,249,
and the liquid blood serum control standard which does not require
reconstitution prior to use as disclosed in U.S. Pat. No.
3,682,835.
A principal raw material used in making these and other such blood
control standards is stored blood plasma obtained from blood donor
centers and blood banks. Blood plasma is normally collected and
stored in various anticoagulant materials such as, for example,
sodium citrate, heparin and sodium ethylenediamine tetraacetate.
Certain widely used anticoagulant materials contain, additionally,
dextrose (D-glucose). ACD blood (containing citric acid, sodium
citrate and dextrose) is a principal example of an anticoagulant
stored blood containing elevated levels of dextrose. Another such
anticoagulant stored blood is CPD blood (containing citrate,
phosphate and dextrose).
Due to the extraneous additon of anticoagulant materials containing
dextrose to the stored blood or blood plasma, the stored product
will contain an elevated, or abnormally high, level of dextrose.
Consequently, such stored blood plasma is not generally suitable
for use as a raw material in the preparation of blood control
standards except in the case of so-called "abnormal" control sera
where high levels of dextrose are desired.
Accordingly, it is an object of the present invention to provide a
blood control standard from anticoagulant stored plasma containing
elevated levels of dextrose.
It is another object of this invention to provide a method for
preparing a blood control standard having normal or reduced levels
of dextrose from stored plasma containing elevated levels of
dextrose without adversely affecting the normal protein
constituents of said blood plasma.
These and other objects of the invention will be apparent to those
skilled in the art after reading the disclosure hereof.
Briefly stated, the objects of the present invention are achieved
by selective destruction of the dextrose in stored blood by aerobic
fermentation with yeast in the negative acceleration phase or in
the stationary phase of the yeast growth. It is important to use
these growth phases in the practice of the present invention,
otherwise the yeast feeds on the blood proteins to make more yeast
cells and the protein content of the product is undesirably
reduced.
Many microorganisms, including yeasts, are capable of dividing at a
rapid rate, e.g., at a frequency of less than once per hour, if
kept under favorable growth conditions. This leads to a
multiplication of cells which is exponential or logarithmic.
Ordinarily, following initial inoculation of a new medium with
spores or with an old culture, a period of little or no growth
occurs. This is referred to as the lag phase. Eventually,
exponential multiplication begins. After a period of time, the
multiplication slows down in what is termed a period of negative
acceleration or the late log phase. Finally, the death of cells
balances or exceeds the formation of new cells in what is termed
the stationary phase. The stationary phase includes the so-called
"real" stationary phase and the phase of decline in growth.
Thus, in the log phase, the cells are growing and dividing whereas
in the stationary phase the cells exhibit little or no growth and
division.
These various phases of yeast growth can be controlled or regulated
by providing suitable conditions of nutrient, oxygen supply, pH,
temperature and inoculant.
A further description of the kinetics of yeast growth and the
foregoing growth phases are found in "The Chemistry and Biology of
Yeasts," edited by A. H. Cook, Academic Press Inc., New York, 1958,
at pages 252 - 275, which is incorporated herein by reference.
It is also important in the practice of the present invention to
use aerobic rather than anerobic fermentation. In the presence of
air (aerobic fermentation) the yeast produces completely oxidized
products, water and carbon dioxide, from dextrose, whereas the
absence of air (anerobic fermentation) results in oxidized products
(carbon dioxide) in part and reduced products (alcohol) in
part.
In a preferred method of the invention, defibrinated plasma or
blood serum is incubated with the yeast for about 12 - 24 hours,
preferably about 18 hours, at normal room temperature (ca.
20.degree.-25.degree. C).
Any available yeast can be used in accordance with this invention.
Yeasts are widely distributed, well-known microorganisms. Even as
early as 1930, some 6,000 cultures of yeast were available from the
Centraalbureau voor Schimmelculturen, Baarn, Holland. The
commercially important yeasts which can be used in the practice of
this invention are those such as Saccharomyces cerevisiae,
Saccharomyses cerevisiae var. ellipsoideus, Saccharomyces
carlsbergensis, Saccharomyces fragilis, and the Torula yeasts,
e.g., Torulopsis spherica, Torulopsis utilis (Candida utilis) and
Candida pseudotropicalis.
Examples of suitable commercially available yeast products are
Fleischmann's Active Dry Yeast marketed by Standard Brands Inc.,
and Red Star Active Dry Yeast, marketed by Universal Foods Corp.
These yeast products are essentially compressed distiller's yeasts.
Preparation of these yeast products from grain alcohol product is
well known and described in many patents, e.g., the early patent of
H. Fleischmann, U.S. Pat. No. 102,387 (Apr. 26, 1870), which is a
modification of the Vienna Process.
The amount of yeast used according to the present invention can
vary somewhat. In general, from about 0.1 gram to about 10 grams of
active dry yeast per liter of blood plasma is suitable and about
one gram per liter is preferred.
Freshly stored ACD blood plasma may contain up to 500 mg. dextrose
per 100 ml. and after 21 days of storage the dextrose level may
still be as high as 300 mg. per 100 ml. In accordance with the
present invention, this dextrose level is reduced to about 0 - 50
mg. per 100 ml., and preferably to about 40 mg. per 100 ml. This
reduction is brought about without any substantial destruction of
the normal protein content of the plasma.
Following the foregoing fermentation, the treated plasma is
filtered or centrifuged to separate particulate residue and the
resulting filtrate or supernatant is retained for use as the base
blood control standard of this invention. Sufficient dextrose can
then be added back to this base control standard to provide any
desired predetermined dextrose level whereby various normal or
abnormal blood control standards can be prepared. For example, the
dextrose level can be increased to a range of from about 80 to
about 400 mg. per 100 ml.
The blood control standard prepared as above can be further treated
to reduce the inorganic ion level, particularly sodium, potassium
and calcium, and/or to remove the lipoprotein components as
described in U.S. Pat. No. 3,682,835. Thus, the above-prepared
material can be admixed with a strong cation exchange resin such as
"Dowex-50" to substantially reduce said cation level, and the
lipoprotein content can be removed by extraction with a fat-solvent
such as a chlorinated hydrocarbon. The treated material is then
conveniently reconstituted with water to about its original volume.
The foregoing treatment can also be carried out prior to the
selective destruction of the dextrose by the aerobic fermentation
with yeast.
The following examples will further illustrate the invention
although the invention is not limited to these specific
examples.
EXAMPLE 1
Pooled human ACD stored blood plasma (10 liters) was obtained from
a blood donor center. Upon assay, the plasma was determined to
contain 345 mg. % (mg. per 100 ml.) of glucose and had a total
protein content of 6.5 gram %. The blood plasma was defibrinated by
reaction with 30,000 units of thrombin (Thrombin Topical, Parke,
Davis & Co., Detroit, Michigan) and then removal of the clotted
material. Upon assay, the defibrinated plasma was determined to
contain 350 mg. % of glucose.
To one liter of the defibrinated plasma was added 1 gram of
Fleischmann's Active Dry Yeast. The mixture was stirred overnight
(about 12 hours) on a magnetic mixer at room temperature (about
20.degree. C). The mixture was then filtered to remove the
particulate matter and the filtrate was retained as the desired
base blood control standard of the present invention. Upon assay,
it was determined to contain 10 mg. % of glucose.
The thus prepared base blood control standard was mixed with 30
grams of "Dowex-50" ion exchange resin in three increments of 10
grams each whereby the Na.sup.+ ion level was reduced from its
original level of 163 meq./liter to 97 meq./liter and the K.sup.+
ion level was reduced from its original level of 11 meq./liter to
4.8 meq./liter. The resin was removed after treatment with each 10
gram increment by filtration through glass wool. Upon assay, the
final product was determined to have a total protein content of 6.3
gram %.
EXAMPLE 2
Another liter of the defibrinated plasma prepared in Example 1,
above, was mixed with 30 grams of "Dowex-50" ion exchange resin in
three increments of 10 grams each whereby the Na.sup.+ ion level
was reduced to 94 meq./liter and the K.sup.+ ion was reduced to 4.4
meq./liter. The resin was removed after treatment with each 10 gram
increment by filtration through glass wool. Upon assay, the
resin-treated plasma was determined to contain 310 mg. % of
glucose.
The resin-treated plasma was then mixed with 1 gram of
Fleischmann's Active Dry Yeast and stirred overnight (about 12
hours) on a magnetic mixer at room temperature (about 20.degree.
C). The mixture was then filtered to remove the particulate matter
and the filtrate was retained as the desired base blood control
standard of the present invention. Upon assay, it was determined to
contain 10 mg. % of glucose and the total protein content was 6.4
gram %.
Various other examples and modifications of the foregoing examples
will be apparent to those skilled in the art after reading the
foregoing specification and the appended claims without departing
from the spirit and scope of the invention. All such further
examples are included within the scope of the invention as defined
by the following claims.
* * * * *